NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating in a report issued on Monday, Zacks reports.
Several other research firms also recently issued reports on NRXP. Weiss Ratings restated a "sell (d-)" rating on shares of NRx Pharmaceuticals in a research report on Tuesday, November 3rd. BTIG Research lifted their target price on NRx Pharmaceuticals from $10.00 to $12.00 and gave the company a "buy" rating in a report on Wednesday, November 11th. HC Wainwright reaffirmed a "buy" rating on shares of NRx Pharmaceuticals in a research note on Tuesday, August 25th. Wolfe Research started coverage on shares of NRx Pharmaceuticals in a report on Thursday, October 15th. They issued an "outperform" rating for the company. Finally, UBS Group reissued a "buy" rating on shares of NRx Pharmaceuticals in a report on Wednesday, August 26th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $35.00.
Read Our Latest Report on NRXP
NRx Pharmaceuticals Stock Up 14.0%
NASDAQ NRXP opened at $2.45 on Monday. The company has a market cap of $106.94 million, a PE ratio of -7.21 and a beta of 2.11. NRx Pharmaceuticals has a 52 week low of $1.62 and a 52 week high of $5.05. The firm's 50-day simple moving average is $2.77 and its two-hundred day simple moving average is $2.97.
NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last posted its quarterly earnings results on Monday, November 16th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.16. The business had revenue of $1.16 million during the quarter, compared to the consensus estimate of $1.28 million. As a group, equities research analysts anticipate that NRx Pharmaceuticals will post -1.14 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the business. Squarepoint Ops LLC bought a new position in shares of NRx Pharmaceuticals in the second quarter worth approximately $54,000. SBI Securities Co. Ltd. lifted its position in NRx Pharmaceuticals by 292.1% during the third quarter. SBI Securities Co. Ltd. now owns 20,001 shares of the company's stock valued at $58,000 after purchasing an additional 14,900 shares during the last quarter. Prime Capital Investment Advisors LLC bought a new stake in NRx Pharmaceuticals during the third quarter valued at approximately $364,000. Commonwealth Equity Services LLC grew its stake in NRx Pharmaceuticals by 30.0% in the 3rd quarter. Commonwealth Equity Services LLC now owns 590,768 shares of the company's stock worth $1,725,000 after buying an additional 136,350 shares in the last quarter. Finally, Marshall Wace LLP grew its stake in NRx Pharmaceuticals by 411.4% in the 3rd quarter. Marshall Wace LLP now owns 995,172 shares of the company's stock worth $2,906,000 after buying an additional 800,592 shares in the last quarter. Hedge funds and other institutional investors own 4.27% of the company's stock.
Top NRx Pharmaceuticals Stories
Investors following NRXP have been watching these stories:
- Positive Sentiment: NRx is targeting a rolling NDA submission for NRX-100 by year-end, with a Yale collaboration intended to support its accelerated-approval pathway. It also announced NRX-200, a subcutaneous ketamine candidate, and an $11.25 million DARPA contract to fund a Phase 3 NRX-101 trial. NRx outlines ketamine market and NRX-100 target
- Neutral Sentiment: Q3 revenue rose to about $1.2 million from $0.2 million a year earlier, and the $0.05-per-share loss was narrower than analyst expectations. However, revenue was below estimates. NRx Q3 results
- Negative Sentiment: Operating loss widened to $8.1 million from $4.0 million year over year, largely amid higher selling and administrative costs tied to the launch. NRx reported $19.8 million in cash at quarter-end, making commercial execution and cash use important risks to monitor. NRx Q3 results and corporate update
About NRx Pharmaceuticals
(
Get Free Report)
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, with a focus on depression and conditions involving suicidal ideation. Its programs are investigational and have not been established as approved treatments. The company's candidates include NRX-100, a preservative-free formulation of ketamine, and NRX-101, an oral combination of D-cycloserine and lurasidone. NRx has studied these therapies for severe depression and bipolar depression, including in patients with suicidal ideation.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider NRx Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NRx Pharmaceuticals wasn't on the list.
While NRx Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.